Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

These two biotechs have a lot in common. Their differences are even more pronounced.

The CRISPR gene-editing tool can be used to silence an important hepatitis B virus gene, a proof-of-concept in vitro study suggests. "It's the first time we've seen CRISPR editing done in a hepatitis ...

An infant with a rare metabolic disease became the world’s first patient to be treated with a personalized CRISPR gene-editing treatment in a landmark study between Penn Medicine and the Children’s ...

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing CRISPR toolbox. The CRISPR ‘gene scissors’ have become an important basis ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

(Nanowerk News) The Molecular Microbiology research group at the University of Alicante (UA) has identified a new enzyme with promising properties for CRISPR-Cas gene editing tools. Named AlCas12a, ...

Related Stories CRISPR gene editing breakthrough eliminates 50% of head, neck tumors CRISPR transforms ordinary fat cells into cancer killing machines Labeling cells with barcodes: New CRISPR ...

Using prime editing, NCF1 mutation is corrected in a 19-year-old with chronic granulomatous disease, an inherited immune disorder, marking a gene therapy milestone.

Three factors will shape development of gene- and other edited therapies over the coming year and beyond. First, commercially speaking, edited therapies still see lower than expected uptake among ...

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...